UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting basal-like breast cancers

Current drug targets, 2012-11, Vol.13 (12), p.1510-1524

2012

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

Journal of clinical oncology, 2003-11, Vol.21 (21), p.3965-3971

2003

Volltextzugriff (PDF)

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

British journal of cancer, 2010-03, Vol.102 (5), p.815-826

2010

Volltextzugriff (PDF)

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

European journal of cancer (1990), 2014-11, Vol.50, p.128-128

2014

Volltextzugriff (PDF)

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality

British journal of cancer, 2008-07, Vol.99 (1), p.1-5

2008

Volltextzugriff (PDF)

Breast cancer trial with erythropoietin terminated unexpectedly

The lancet oncology, 2003-08, Vol.4 (8), p.459-460

Leyland-Jones, Brian

2003

Volltextzugriff (PDF)

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S548-S548

2015

Volltextzugriff (PDF)

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

European journal of cancer (1990), 2012-11, Vol.48, p.115-115

2012

Volltextzugriff (PDF)

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

European journal of cancer (1990), 2012-11, Vol.48, p.114-115

2012

Volltextzugriff (PDF)

Variation in RNA expression and genomic DNA content acquired during cell culture

British journal of cancer, 2004-01, Vol.90 (2), p.476-482

2004

Volltextzugriff (PDF)

Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease

European journal of cancer supplements, 2004-04, Vol.2 (5), p.9-12

Leyland-Jones, B.

2004

Volltextzugriff (PDF)

Of mice and men: the evolution of animal welfare guidelines for cancer research

British journal of cancer, 2010-05, Vol.102 (11), p.1553-1554

2010

Volltextzugriff (PDF)

PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?

European journal of cancer (1990), 2011, Vol.47, p.S16-S16

2011

Volltextzugriff (PDF)

P068 Sequencing to identify potential targets of resistance to primary therapy

Breast (Edinburgh), 2015-03, Vol.24, p.S50-S50

2015

Volltextzugriff (PDF)

P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy

Breast (Edinburgh), 2015-03, Vol.24, p.S43-S43

2015

Volltextzugriff (PDF)

P024 Navigating genomic landscape: PI3KSIGNALING algorithm for rational combination in precision medicine

Breast (Edinburgh), 2015-03, Vol.24, p.S34-S34

2015

Volltextzugriff (PDF)

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

European journal of cancer (1990), 2011, Vol.47, p.S17-S17

2011

Volltextzugriff (PDF)

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5960-5972

2005

Volltextzugriff (PDF)

Trastuzumab: hopes and realities

The lancet oncology, 2002-03, Vol.3 (3), p.137-144

Leyland-Jones, Brian

2002

Volltextzugriff (PDF)

Proteomics: New technologies and clinical applications

European journal of cancer (1990), 2008-12, Vol.44 (18), p.2737-2741

2008

Volltextzugriff (PDF)

Comparative analysis of xanafide cytotoxicity in breast cancer cell lines

British journal of cancer, 2007-07, Vol.97 (1), p.58-64

2007

Volltextzugriff (PDF)

Maximizing the response to Herceptin® therapy through optimal use and patient selection

Anti-cancer drugs, 2001-12, Vol.12 Suppl 4, p.S11-S17

Leyland-Jones, B

2001

Volltextzugriff (PDF)

S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank

European journal of cancer supplements, 2007, Vol.5 (8), p.5-5

Leyland-Jones, B

2007

Volltextzugriff (PDF)

Hypersensitivity reactions from taxol

Journal of clinical oncology, 1990-07, Vol.8 (7), p.1263-1268

1990

Volltextzugriff (PDF)

Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer

European journal of cancer (1990), 2005-07, Vol.41 (11), p.1515-1527

2005

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)

Publikationsform

Artikel
(89)
Berichte
(1)

Sprache

Englisch
(90)

Erscheinungsjahr

n.n

Thema

Humans
(54)
Science & Technology
(53)
Life Sciences & Biomedicine
(52)
Oncology
(43)
Biological And Medical Sciences
(26)
Female
(26)
Medical Sciences
(25)
Pharmacology. Drug Treatments
(20)
Animals
(17)
Antineoplastic Agents
(14)
Breast Neoplasms - Drug Therapy
(14)
Hematology, Oncology And Palliative Medicine
(14)
Antineoplastic Agents - Therapeutic Use
(13)
Breast Neoplasms - Pathology
(13)
Chemotherapy
(13)
Tumors
(12)
Breast Cancer
(11)
Neoplasms - Drug Therapy
(11)
Pharmacology & Pharmacy
(11)
Aged
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting basal-like breast cancers

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality

Breast cancer trial with erythropoietin terminated unexpectedly

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

Variation in RNA expression and genomic DNA content acquired during cell culture

Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease

Of mice and men: the evolution of animal welfare guidelines for cancer research

PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?

P068 Sequencing to identify potential targets of resistance to primary therapy

P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy

P024 Navigating genomic landscape: PI3KSIGNALING algorithm for rational combination in precision medicine

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Trastuzumab: hopes and realities

Proteomics: New technologies and clinical applications

Comparative analysis of xanafide cytotoxicity in breast cancer cell lines

Maximizing the response to Herceptin® therapy through optimal use and patient selection

S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank

Hypersensitivity reactions from taxol

Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer

Aktive Filter

Suchergebnisse filtern